Background
On 10 March 2026, the Ministry of Health of Cambodia participated in a technical-level bilateral meeting with the Ministry of Health of the Lao People’s Democratic Republic through a virtual platform. The Cambodian side was led by Secretary of State Dr. Soeng Vinda, and the Lao side was represented by Dr. Bounxou Keohavong, Director of the Cabinet of the Ministry of Health.
According to the ministry’s statement, both sides exchanged views on improving resilient health systems and shared experience on pharmaceutical management. The discussion placed particular emphasis on joint efforts to manage and prevent counterfeit medicines, falsified medicines, poor-quality or substandard medicines, and the circulation of unregistered medical products.
Scope of Application
The discussions concerned bilateral cooperation between the health authorities of Cambodia and Laos in the field of public health, with a focus on pharmaceutical and medical product governance. The statement indicates that the parties discussed possible future cooperation covering information exchange on medicine registration systems, strengthening enforcement of laws and procedures governing pharmaceutical and medical products, and capacity building for health officials, including in pharmaceutical matters.
Key Provisions or Decisions
The meeting did not announce a signed instrument, but it stated that both sides discussed the possibility of preparing a new memorandum of understanding on cooperation in public health.
The areas identified for potential cooperation were:
1. Exchange of information on medicine registration systems.
2. Strengthening implementation of laws and procedures for the management of pharmaceutical and medical products.
3. Strengthening the capacity of health officials, including in pharmaceutical fields.
The two sides also expressed a shared commitment to promoting the quality and safety of pharmaceutical and medical products in line with international standards, with the stated aim of contributing to public health protection and progress toward universal health coverage.
Implications for Investors, Businesses, or Compliance
The statement is relevant for entities involved in pharmaceuticals, medical products, importation, registration, and distribution because it signals continued cross-border institutional cooperation between Cambodia and Laos on medicine quality, product safety, and oversight of unregistered or falsified products.
It also indicates possible future coordination on registration information exchange and enforcement procedures. However, no new binding compliance requirements, penalties, or formal regulatory changes were announced in this update.
Official Source
Ministry of Health of Cambodia, official statement on a technical bilateral meeting between the Ministries of Health of Cambodia and Laos, published 11 March 2026.
